Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma
NCT ID: NCT03480087
Last Updated: 2022-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
118 participants
OBSERVATIONAL
2015-01-31
2022-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma
NCT07041827
Prediction of Delayed Toxic Cardiomyopathy in Children
NCT05781672
Stress Echocardiography to Identify Chemotherapy Induced Cardiotoxicity in Cancer Patients With Heart Failure Risk
NCT05950399
Magnetic Resonance Imaging:A Window to Anthracycline Toxicity
NCT03211520
Cardiovascular Diagnostic in Assessment of Risk HDS and HCT in Patients With Haemoblasts.
NCT05508087
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chemotherapy alone
Patient treated with anthracycline containing chemotherapy
No interventions assigned to this group
Chemotherapy plus radiotherapy
Patient treated with anthracycline containing chemotherapy followed by mediastinal radiotherapy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of Hodgkin Disease (HD) or Primary Mediastinal B-cell lymphoma (PMBCL) or diffuse large B-cell lymphoma (DLBCL)
* Disease requiring treatment with anthracycline containing regimen only (cohort A) or anthracycline containing regimen followed by mediastinal radiotherapy (cohort B)
* Written informed consent
Exclusion Criteria
* Unable to perform anthracyline containing regimen
* Previous treatment with mediastinal radiotherapy
* Kidney failure (defined as creatinine x2 UNL) or liver failure (defined as AST and ALT x2 UNL)
* ECOG PS \> 2
* Echocardiographic acoustic windows not suitable for strain evaluation
* Any other conditions or situations preventing patients to sign informed consent
19 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
A.O.U. Città della Salute e della Scienza
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mario Levis
Medical doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SC Ematologia - AOU Città della salute e della Scienza di Torino
Torino, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Cardiocare
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.